Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer

Stopped early · Not applicable

Conditions studied: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage I Cervical Cancer

In brief

This clinical trial is studying how well lymph node mapping and sentinel lymph node identification work in finding lymph node metastases in patients with stage IB1 cervical cancer. Diagnostic procedures, such as lymph node mapping and sentinel lymph node identification, performed before and during surgery, may improve the ability to detect lymph node metastases in patients who have cervical cancer.

Key facts

Study ID

NCT00070317

Run by

Gynecologic Oncology Group

People needed

102

Starts

2004-06-01

Expected to finish

2013-01-01

Last updated by the study team

2017-11-06

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of carcinoma of the cervix of 1 of the following cellular types:
• Squamous cell carcinoma
• Adenocarcinoma
• Adenosquamous cell carcinoma
• Stage IB1 disease (no greater than 4 cm)
• No unequivocal evidence of metastases
• Adequate surgical candidate
• No known allergy to triphenylmethane compounds
• No prior pelvic irradiation
• No prior retroperitoneal surgery
• More than 4 weeks since prior cold knife or loop electrosurgical excision procedure (LEEP) cone biopsy
• Prior cone biopsy allowed provided current disease is stage IB1

Where it is running

• Gynecologic Oncology Group — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.